Grifols S.A.

17.82+0.3100+1.77%Vol 573.77K1Y Perf -10.09%
Apr 13th, 2021 15:54 DELAYED
BID17.81 ASK17.82
Open17.70 Previous Close17.51
Pre-Market- After-Market-
 - -%  - -
Target Price
18.50 
Analyst Rating
Moderate Buy 2.20
Potential %
3.76 
Finscreener Ranking
★★★     49.75
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     54.22
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     55.48
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
+     29.38
Market Cap12.25B 
Earnings Rating
Neutral
Price Range Ratio 52W %
42.57 
Earnings Date
20th Apr 2021

Today's Price Range

17.6617.97

52W Range

14.8121.88

5 Year PE Ratio Range

13.1028.70

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
2.70%
1 Month
8.89%
3 Months
-9.04%
6 Months
-4.54%
1 Year
-10.09%
3 Years
-16.26%
5 Years
14.46%
10 Years
-

TickerPriceChg.Chg.%
GRFS17.820.31001.77
AAPL134.353.11002.37
GOOG2 268.1113.32000.59
MSFT258.542.63001.03
XOM55.660.16000.29
WFC39.83-0.9400-2.31
JNJ159.43-2.2100-1.37
FB309.61-1.9300-0.62
GE13.45-0.1400-1.03
JPM154.30-1.6500-1.06
Financial StrengthValueIndustryS&P 500US Markets
0.80
2.40
0.56
1.35
4.90
Leverage Ratio 2.90
ProfitabilityValueIndustryS&P 500US Markets
42.20
20.90
26.80
16.50
12.49
RevenueValueIndustryS&P 500US Markets
5.05B
7.40
8.24
6.46
DividendsValueIndustryS&P 500US Markets
1.75
0.31
-18.54
1.95
Payout ratio20.00
Earnings HistoryEstimateReportedSurprise %
Q04 20200.380.29-23.68
Q03 20200.340.365.88
Q02 20200.370.35-5.41
Q01 20200.240.254.17
Q04 20190.310.310.00
Q03 20190.310.28-9.68
Q02 20190.330.330.00
Q01 20190.250.250.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.310.00-
6/2021 QR0.380.00-
12/2021 FY1.36338.71Positive
12/2022 FY1.62326.32Positive
Next Report Date20th Apr 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %9.70
Volume Overview
Volume573.77K
Shares Outstanding687.55M
Trades Count4.23K
Dollar Volume24.57M
Avg. Volume948.70K
Avg. Weekly Volume928.32K
Avg. Monthly Volume1.03M
Avg. Quarterly Volume995.43K

Grifols S.A. (NASDAQ: GRFS) stock closed at 17.51 per share at the end of the most recent trading day (a -2.72% change compared to the prior day closing price) with a volume of 1.25M shares and market capitalization of 12.25B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 23655 people. Grifols S.A. CEO is Raimon Grifols Roura / Víctor Grifols Deu.

The one-year performance of Grifols S.A. stock is -10.09%, while year-to-date (YTD) performance is -5.04%. GRFS stock has a five-year performance of 14.46%. Its 52-week range is between 14.81 and 21.88, which gives GRFS stock a 52-week price range ratio of 42.57%

Grifols S.A. currently has a PE ratio of 16.30, a price-to-book (PB) ratio of 1.99, a price-to-sale (PS) ratio of 2.37, a price to cashflow ratio of 9.20, a PEG ratio of 2.32, a ROA of 4.60%, a ROC of 6.88% and a ROE of 14.28%. The company’s profit margin is 12.49%, its EBITDA margin is 26.80%, and its revenue ttm is $5.05 Billion , which makes it $7.40 revenue per share.

Of the last four earnings reports from Grifols S.A., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Grifols S.A.’s next earnings report date is 20th Apr 2021.

The consensus rating of Wall Street analysts for Grifols S.A. is Moderate Buy (2.2), with a target price of $18.5, which is +3.76% compared to the current price. The earnings rating for Grifols S.A. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Grifols S.A. has a dividend yield of 1.75% with a dividend per share of $0.31 and a payout ratio of 20.00%.

Grifols S.A. has a Neutral technical analysis rating based on Technical Indicators (ADX : 12.27, ATR14 : 0.69, CCI20 : 96.68, Chaikin Money Flow : -0.07, MACD : -0.44, Money Flow Index : 74.87, ROC : 3.49, RSI : 28.72, STOCH (14,3) : 70.00, STOCH RSI : 0.00, UO : 59.08, Williams %R : -30.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Grifols S.A. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (60.00 %)
3 (60.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (20.00 %)
2 (40.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (20.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.20
Moderate Buy
1.80
Strong Buy
1.00

Grifols S.A.

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 78% of sales in 2019. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics is now roughly 14% of revenue following the Novartis and Hologic deals.

CEO: Raimon Grifols Roura / Víctor Grifols Deu

Telephone: +34 935710500

Address: Avinguda de la Generalitat, 152-158, Barcelona 08174, , ES

Number of employees: 23 655

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

46%54%

Bearish Bullish

59%41%

News

Stocktwits